# Stemgent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stemgent

- Industry: Biotechnology
- Headquarters: Lexington, US
- Total disclosed funding: $38M
- Latest round: Series C (Feb 1, 2012)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2007, Stemgent Inc. operates as a biotechnology firm that offers tools and resources for stem cell research. The company was founded by Ian Ratcliffe. In August 2012, Stemgent raised a USD 11.3 million unspecified round of financing from undisclosed investors.

Stemgent provides tools for stem cell research, with a particular emphasis on cellular reprogramming, a technique for converting adult cells into induced pluripotent stem cells (iPSCs). The firm offers a range of tools specifically designed for generating iPSCs, including cell lines, small molecules, and antibodies. The firm offers human iPSC-derived cells, collagen products, small molecules, and perfusion plates. In addition, the firm offers training courses focused on cellular reprogramming.

## Funding rounds

- Series C, Feb 1, 2012, $6.3M — HealthCare Ventures, Morgenthaler Ventures
- Series B, Jul 19, 2010, $5.6M — HealthCare Ventures, Morgenthaler Ventures
- Series B, Apr 30, 2010, $5.6M — HealthCare Ventures
- Series B, Mar 9, 2009, $14M — HealthCare Ventures, Morgenthaler Ventures
- Series A, Jun 26, 2008, $6.5M — HealthCare Ventures

## Investors

- HealthCare Ventures — Series A, Series B, Series C
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series B, Series C